According to a new proposal by the Center for American Progress, Medicare and private health insurance companies should have the power to negotiate drug prices with manufacturers, empowered by comparative effectiveness research data.
The effort to reach young adults will allow them to shop for coverage entirely on mobile digital technology. But an economist interviewed earlier this month says it might not be enough.
Both private and public healthcare plans have traditionally used patient cost sharing to keep costs down. However, implementing value-based insurance design may be able to promote efficiency while increasing the use of high-quality care.
Use of stereotactic body radiation therapy improved survival in elderly patients diagnosed with early-stage non-small cell lung cancer by about 20% over a decade.
What we're reading, September 27, 2016: a panel of experts recommends expanding preventive services for women with no cost sharing; BlueCross BlueShield of Tennessee is exiting 3 Obamacare exchanges; and Pfizer will not split into 2 companies.
The new guideline comes as FDA weighs an advisory panel recommendation for CGM dosing, which many see as a first step toward Medicare coverage.
Analysis of prescription transaction data provided insight into reduced out-of-pocket spending and increased medical fill rates for people who gained coverage under the Affordable Care Act and had at least 1 chronic condition.
A new study by researchers at the Perelman School of Medicine has identified a predictive biomarker in stage IV patients with melanoma being treated with the pembrolizumab.
Diabetes Compendium
HCV Compendium
Oncology Compendium
Reimbursement Compendium
Know Your News
HF Compendium